Join our daily newsletter At The Bell to receive exclusive market insights
- ResApp Health (RAP) has signed a memorandum of understanding (MoU) with RB to develop an app that uses its ResAppDx-EU respiratory test
- RB is a global health, hygiene, and nutrition products manufacturer that is known for brands such as Dettol, Nurofen, Clearasil, and Air Wick
- Under this MoU, both companies will work together to develop a prototype app which will be used by customers to assess their respiratory symptoms
- If a joint development is not signed within six months, then either party can terminate the partnership
- ResApp is steady on the market this morning and shares are trading for 19 cents each
ResApp Health (RAP) has signed a memorandum of understanding with RB to develop an app that uses its ResAppDx-EU respiratory test.
RB is a global health, hygiene, and nutrition products manufacturer that is known for brands such as Dettol, Nurofen, Clearasil, and Air Wick.
Under this MoU, both companies will work together to build and test a prototype app which will be used by customers to self-assess — or assess with the aid of a pharmacist — their respiratory symptoms.
This partnership will make use of ResApp’s regulatory-approved ResAppDx-EU test, which is used for the diagnosis of multiple respiratory problems.
All users have to do is cough into the phone and the machine learning algorithms analyse the sounds to diagnose the disease and provide quick and accurate information.
It runs on smartphones and does not need any additional hardware or accessories to be used.
If a joint development is not signed within six months, then either party can terminate the partnership.
ResApp is steady on the market this morning and shares are trading for 19 cents each at 10:33 am AEST.
